Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease

Next Previous
Trial Profile

A Randomized, Placebo-controlled, Double-blind, Parallel-group Phase 2a Exploratory Study With Placebo run-in to Investigate PK/PD Effects, Safety, Tolerability and Pharmacokinetics of REM0046127 Oral Suspension Compared With Placebo in Subjects With Mild to Moderate Alzheimer's Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs REM 0046127 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors reMYND

Most Recent Events

  • 03 Apr 2025 According to a a reMYND Media Release, the company has recently collaborated with Unlearn- a leader in AI solutions for clinical trials, to focus on on remynd's Phase 2a clinical trial of REM127. Unlearn supported the study by applying its Alzheimer's Disease-specific Digital Twin Generator (AD DTG). These digital twins served as individualized comparators, providing additional evidence for interpreting and extrapolating the changes observed in the treated population.
  • 04 Jun 2024 Status changed from recruiting to discontinued. (Reason the study was stopped: Due to the event of repeated elevated transaminase levels in one subject - elevated ALT/AST up to 6x ULN in the absence of any other potential underlying cause - we have decided to terminate the study.)
  • 26 Apr 2024 This trial has been discontinued in Spain.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top